var data={"title":"Sodium thiosulfate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sodium thiosulfate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6976?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sodium-thiosulfate-drug-information\" class=\"drug drug_general\">see &quot;Sodium thiosulfate: Drug information&quot;</a> and <a href=\"topic.htm?path=sodium-thiosulfate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sodium thiosulfate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062295\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Cyanide</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Extravasation</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062291\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sodium-thiosulfate-drug-information\" class=\"drug drug_general\">see &quot;Sodium thiosulfate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cyanide poisoning:</b> Infant, Children, and Adolescents: <b>Note:</b> Administer in conjunction with sodium nitrite. Administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: IV 250 mg/kg (1 mL/kg of a 25% solution); maximum dose 12.5 <b>g</b> (50 mL of a 25% solution). Monitor patients for 24 to 48 hours; if symptoms return, repeat both sodium nitrite and sodium thiosulfate at one-half the original doses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: IV: 500 mg/kg (2 mL/kg of a 25% solution); maximum dose: 12.5 <b>g</b> (50 mL of a 25% solution). Monitor the patient for 24 to 48 hours; if symptoms return, repeat both sodium nitrite and sodium thiosulfate at one-half the original doses (Howland, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Extravasation management:</b> Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Mechlorethamine extravasation:</i> Children and Adolescents, SubQ: 1/6 M (~4%) solution: Inject 2 mL for each mg of mechlorethamine suspected to have extravasated (P&eacute;rez Fidalgo, 2012; Polovich, 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cisplatin extravasation, concentrated:</i> Infants, Children, and Adolescents: Inject 2 mL of a 1/6 M (~4%) sodium thiosulfate solution into existing IV line for each 100 mg of cisplatin extravasated; consider also injecting 1 mL of a 1/6 M (~4%) sodium thiosulfate solution as 0.1 mL subcutaneous injections (clockwise) into the area around the extravasation, may repeat subcutaneous injections several times over the next 3 to 4 hours (Ener, 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cyanide poisoning:</b> IV: <b>Note:</b> Administer in conjunction with sodium nitrite. Administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate: 12.5 g (50 mL of a 25% solution); may repeat at one-half the original dose if symptoms of cyanide toxicity return. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Extravasation management:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Mechlorethamine extravasation:</i> SubQ: Inject 2 mL of a 1/6 M (~4%) sodium thiosulfate solution (into the extravasation site) for each mg of mechlorethamine suspected to have extravasated (P&eacute;rez Fidalgo, 2012; Polovich, 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cisplatin extravasation, concentrated:</i> Inject 2 mL of a 1/6 M (~4%) sodium thiosulfate solution into existing IV line for each 100 mg of cisplatin extravasated; consider also injecting 1 mL of a 1/6 M (~4%) sodium thiosulfate solution as 0.1 mL subcutaneous injections (clockwise) into the area around the extravasation, may repeat subcutaneous injections several times over the next 3 to 4 hours (Ener, 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bendamustine extravasation:</i> SubQ: Bendamustine extravasation may be managed with 1/6 M (~4%) sodium thiosulfate solution in the same manner as mechlorethamine extravasation (Schulmeister, 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, renal elimination of sodium thiosulfate is significant and risk of adverse effects may be increased in patients with renal impairment. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222284\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10% [100 mg/mL] (10 mL [DSC]); 25% [250 mg/mL] (50 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222272\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062298\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Route of administration dependent upon use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: <b>Cyanide poisoning:</b> Administer undiluted (25% solution) by IV infusion over 10 to 30 minutes immediately after the administration of sodium nitrite (Howland, 2011). Decrease rate of infusion in the event of significant hypotension. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">SubQ: <b>Extravasation management:</b> Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do <b>NOT</b> flush the line); remove needle/cannula (temporarily keep in place for cisplatin extravasation to allow for sodium thiosulfate administration through the needle/cannula); elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mechlorethamine: Inject subcutaneously 1/6 M (~4%) sodium thiosulfate solution into the extravasation site using &le;25-gauge needle; change needle with each injection (P&eacute;rez Fidalgo 2012; Polovich 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cisplatin, concentrated: Inject 1/6 M (~4%) sodium thiosulfate solution into the existing IV line; also consider administering subcutaneous injections (clockwise) into the area around the extravasation using a new 25- or 27-gauge needle for each injection (Ener 2004)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10076269\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. Do not freeze.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Extravasation management (off-label use/route): Store the 1/6 M solution for SubQ administration at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F) (Polovich 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062297\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Treatment of cyanide poisoning [FDA approved in pediatric patients (age not specified) and adults]; has also been used for used in the management of mechlorethamine extravasation, management of concentrated cisplatin (&ge;0.4 mg/mL) extravasation; management of bendamustine extravasation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222319\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Disorientation, flushing sensation, headache, salty taste</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Prolonged bleeding time</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222290\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed within the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222276\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fire victims: Fire victims may present with both cyanide and carbon monoxide poisoning. In these patients, the induction of methemoglobinemia with amyl nitrite or sodium nitrite is contraindicated until carbon monoxide levels return to normal due to the risk of tissue hypoxia. Methemoglobinemia decreases the oxygen-carrying capacity of hemoglobin and the presence of carbon monoxide prevents hemoglobin from releasing oxygen to the tissues. In this scenario, sodium thiosulfate may be used alone to promote the clearance of cyanide. However, hydroxocobalamin is the preferred cyanide antidote and should be be considered to avoid the nitrite-related problems and because sodium thiosulfate has a slow onset of action.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfite hypersensitivity: The presence of sulfite hypersensitivity should not preclude the use of this medication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Cyanide poisoning: Due to the risk for serious adverse effects, use with caution in patients where the diagnosis of cyanide poisoning is uncertain. However, if clinical suspicion of cyanide poisoning is high, treatment should not be delayed. Signs of cyanide poisoning may include altered mental status, mydriasis, nausea/vomiting, dyspnea, chest tightness, hyper-/hypotension, plasma lactate &ge;8 mmol/L. Treatment of cyanide poisoning should include external decontamination and supportive therapy.  Consider consultation with a poison control center at 1-800-222-1222.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Initiation of treatment: Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of highly suspected or confirmed cyanide toxicity. Pretreatment levels may be useful as postinfusion levels may be inaccurate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Return of symptoms: Patients receiving treatment for acute cyanide toxicity must be monitored for return of symptoms for 24-48 hours; repeat treatment (one-half the original dose) should be administered if symptoms return.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300072\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6223035\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12800&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222280\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222293\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not observed in animal reproduction studies of sodium thiosulfate. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15235396\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyanide poisoning: Monitor for at least 24-48 hours after administration; blood pressure and heart rate during and after infusion; hemoglobin/hematocrit; co-oximetry; serum lactate levels; venous-arterial PO<sub>2</sub> gradient; serum methemoglobin and oxyhemoglobin. Pretreatment cyanide levels may be useful diagnostically.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extravasation management: Monitor and document extravasation site for pain, blister formation, skin sloughing, arm/hand swelling/stiffness; monitor for fever, chills, or worsening pain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222275\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cyanide toxicity: Serves as a sulfur donor in rhodanese-catalyzed formation of thiocyanate (much less toxic than cyanide)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Extravasation management: Neutralizes the reactive species of mechlorethamine; reduces the formation of hydroxyl radicals which cause tissue injury</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222289\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Thiosulfate: ~3 hours (Howland 2011); Thiocyanate: ~3 days; Renal impairment: &le;9 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~20% to 50% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323882\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sodium Thiosulfate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $107.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038829\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Krem Ochronny z Tiosiarczanem Sodu A (PL);</li>\n      <li>Soft Mate Consept 2 (PL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. <i>Ann Oncol</i>. 2004;15(6):858-862. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/15151940/pubmed\" target=\"_blank\" id=\"15151940\">15151940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Geller RJ, Barthold C, Saiers JA, et al, &quot;Pediatric Cyanide Poisoning: Causes, Manifestations, Management, and Unmet Needs,&quot; <i>Pediatrics</i>, 2006, 118(5):2146-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/17079589/pubmed\" target=\"_blank\" id=\"17079589\">17079589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gracia R and Shepherd G, &quot;Cyanide Poisoning and Its Treatment,&quot; <i>Pharmacotherapy</i>, 2004, 24(10):1358-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/15628833/pubmed\" target=\"_blank\" id=\"15628833\">15628833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hall AH, Dart R, and Bogdan G, &ldquo;Sodium Thiosulfate or Hydroxocobalamin for the Empiric Treatment of Cyanide Poisoning?&rdquo; <i>Ann Emerg Med</i>, 2007, 49(6):806-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/17098327/pubmed\" target=\"_blank\" id=\"17098327\">17098327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howland MA, &ldquo;Antidotes in Depth: Sodium and Amyl Nitrite,&rdquo; <i>Goldfrank's Toxicologic Emergencies</i>, 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011, 1519-22.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howland MA, &ldquo;Antidotes in Depth: Sodium Thiosulfate,&rdquo; <i>Goldfrank's Toxicologic Emergencies</i>, 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo; <i>Chest</i>, 2003, 123(3):897-922.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/12628894/pubmed\" target=\"_blank\" id=\"12628894\">12628894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. <i>Ann Oncol</i>. 2012;23(Suppl 7):167-173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polovich M, Whitford JN and Olsen M, <i>Chemotherapy and Biotherapy Guidelines and Reccomendations for Practice</i>, 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12800 Version 68.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062295\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062291\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F222284\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F222272\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062298\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F10076269\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062297\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F222319\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F222290\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F222276\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300072\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6223035\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F222280\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F222293\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15235396\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F222275\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F222289\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323882\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038829\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12800|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sodium-thiosulfate-drug-information\" class=\"drug drug_general\">Sodium thiosulfate: Drug information</a></li><li><a href=\"topic.htm?path=sodium-thiosulfate-patient-drug-information\" class=\"drug drug_patient\">Sodium thiosulfate: Patient drug information</a></li></ul></div></div>","javascript":null}